Viz.ai, a San Francisco, CA, and Tel Aviv, Israel and -based AI-powered disease detection and care coordination platform, raised a $100m serial D funding round at a $1.2 billion valuation.
The round was led by Tiger Global and Insight Partners with participation from early backers, including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.
The company intends to use the new funds to expand the platform to detect and triage additional diseases and grow its customer base globally.
Led by Chris Mansi, MD, co-founder, and CEO, Viz.ai leverages AI algorithms and machine learning to extend the speed of diagnosis and care for a variety of acute and emergent diseases across hospitals and health systems. The intelligent care coordination solution unifies synchronized care collaboration, hi-fi mobile image viewing, automated workflows, and improved visibility at decision-making moments. Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save lots of time and improve patient outcomes and access to care and is used in more than 1,000 hospitals within the US and EMEA. Customers include Sinai Health System, Jefferson University, Banner Health, CommonSpirit Health, and HCA Healthcare, which is additionally an investor.
The company is located in San Francisco, Tel Aviv, Portugal, and Amsterdam.